Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses
- PMID: 2512330
- PMCID: PMC304057
- DOI: 10.1172/JCI114364
Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses
Abstract
Antibody opsonins from cystic fibrosis (CF) patients were investigated using nonmucoid and mucoid lipopolysaccharide (LPS) immunotype 1 Pseudomonas aeruginosa as bacterial ligands and PMN phagocytes. CF sera were compared to normal sera, polyvalent PA LPS hyperimmune globulin, and isotype switch variant monoclonal antibodies (MAbs) specific for type 1 PA LPS. Sera from PA-infected CF patients (CF PA+) had elevated levels of PA LPS and alginate IgG antibodies and promoted significantly greater antibody-dependent PMN chemiluminescence responses than sera from uninfected CF patients (CF PA-) or normal human sera (NHS). After adjustment for autologous IgG PA LPS antibody content, however, CF PA+ sera had less antibody-dependent opsonic activity than sera from CF PA- patients (P less than 0.025) or NHS (P less than 0.0025), suggesting qualitative opsonic defects of IgG PA LPS antibodies in CF PA+ sera. Antigen-specific immunoprecipitation of PA LPS antibodies enhanced opsonization by 40% of CF PA+ sera while uniformly reducing that from CF PA- sera (P less than 0.01), indicating LPS-specific nonopsonic antibodies in some CF PA+ sera. Alginate antibodies were not critical opsonins in most uninfected CF patient sera. PA LPS IgG antibodies isolated by immunoaffinity chromatography from NHS, hyperimmune globulin, and CF PA- sources were opsonic and had greater activity at equal antigen-binding concentration than identical antibodies isolated from infected CF patients (P less than 0.01-0.05); the majority of isolates from CF PA+ sera did not promote PMN oxidative responses above nonopsonic baseline. A potential isotypic basis for these findings was supported by differences in PMN responses to PA opsonized with MAbs of identical specificity but differing isotypes. PA LPS-specific IgG antibodies inhibiting PMN oxidative responses in infected patient sera demonstrate antigen-specific immunomodulation of host responses by chronic bacterial parasitism in CF, which may play a role in the pathophysiology of lung disease.
Similar articles
-
Lipopolysaccharide (LPS), LPS-immune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.APMIS Suppl. 1995;50:1-30. APMIS Suppl. 1995. PMID: 7756034
-
Serotype-specific serum IgG antibodies to lipopolysaccharides of Pseudomonas aeruginosa in cystic fibrosis: correlation to disease, subclass distribution, and experimental protective capacity.Pediatr Res. 1990 May;27(5):508-13. doi: 10.1203/00006450-199005000-00019. Pediatr Res. 1990. PMID: 2111907
-
Opsonization of mucoid and non-mucoid Pseudomonas aeruginosa by serum from patients with cystic fibrosis assessed by a chemiluminescence assay.Clin Invest Med. 1982;5(2-3):125-8. Clin Invest Med. 1982. PMID: 6811181
-
Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.Behring Inst Mitt. 1997 Feb;(98):350-60. Behring Inst Mitt. 1997. PMID: 9382760 Review.
-
Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.APMIS Suppl. 2003;(116):1-47. APMIS Suppl. 2003. PMID: 14692154 Review.
Cited by
-
Mucosal Immunity in Cystic Fibrosis.J Immunol. 2021 Dec 15;207(12):2901-2912. doi: 10.4049/jimmunol.2100424. J Immunol. 2021. PMID: 35802761 Free PMC article. Review.
-
Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects.Infect Immun. 2006 Feb;74(2):968-74. doi: 10.1128/IAI.74.2.968-974.2006. Infect Immun. 2006. PMID: 16428742 Free PMC article. Clinical Trial.
-
Amount and Avidity of IgG Antibodies to Pseudomonas Aeruginosa Exotoxin A Antigen in Cystic Fibrosis Patients.Pathol Oncol Res. 1997;3(1):26-29. doi: 10.1007/BF02893348. Pathol Oncol Res. 1997. PMID: 11173620
-
Lymphocytes in cystic fibrosis lung disease: a tale of two immunities.Clin Exp Immunol. 2004 Mar;135(3):358-60. doi: 10.1111/j.1365-2249.2003.02389.x. Clin Exp Immunol. 2004. PMID: 15008966 Free PMC article. No abstract available.
-
Eosinophilic activation in cystic fibrosis.Thorax. 1994 May;49(5):496-9. doi: 10.1136/thx.49.5.496. Thorax. 1994. PMID: 8016773 Free PMC article.